Silexion Therapeutics Submits Regulatory Application To Israel For Its Phase 2/3 Clinical Study Of SIL204 In Participants With Locally Advanced Pancreatic Cancer

Silexion Therapeutics, a clinical-stage biotechnology company advancing RNA-based therapies for oncology, today announced the initiation of its regulatory application in Israel for its planned Phase 2/3 clinical trial of SIL204 in patients with locally advanced pancreatic cancer (LAPC), based on the positive Scientific Advice response received from the German Federal Institute for Drugs and Medical Devices (BfArM).

The submission represents a key regulatory milestone in the Company's clinical development program and advances Silexion toward initiating human trials with SIL204, which are planned for the second quarter of 2026. The application is further supported by two recently completed species toxicology studies confirming no systemic organ toxicity. Silexion plans to file regulatory applications in Germany and the European Union in the first quarter of 2026, with expansion to U.S. clinical sites anticipated following completion of the safety run-in in Israel and Germany.

The submissions in Israel are being conducted in collaboration with Sheba Medical Center, ranked among the top ten hospitals worldwide by Newsweek1, where the Company plans to conduct the Israeli portion of its planned Phase 2/3 clinical trial, subject to applicable regulatory and ethics approvals.